A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer

Nima Sharifi, Akinobu Hamada, Tristan Sissung, Romano Danesi, David Venzon, Caitlin Baum, James L. Gulley, Douglas K. Price, William L. Dahut, William D. Figg

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

OBJECTIVE: To determine if patients with advanced prostate cancer carrying a polymorphism that codes for a more active testosterone transporter have less durable responses to androgen-deprivation therapy (ADT) than patients not carrying this polymorphism. PATIENTS AND METHODS: We previously determined that a polymorphism in SLCO1B3 affects testosterone transport and that those men who have at least one wild-type T allele at the 334 T > G polymorphism in this gene have a shorter survival. We hypothesized that the T allele which increases testosterone transport would be associated with a shorter interval from ADT to androgen independence. We examined the association between this SLCO1B3 polymorphism and time from ADT to androgen independence, ADT to prostate-specific antigen (PSA) nadir and PSA nadir to androgen independence in 68 Caucasian patients with advanced prostate cancer who were treated with ADT with metastatic disease (D2) or biochemical failure with no metastatic disease (D0). RESULTS: When examined separately, patients in the individual stages tended to have a shorter time to androgen independence with the T allele in the D0 (P = 0.11) and D2 (P = 0.18) groups. Combining these groups and stratifying by stage yielded a statistically significant shorter time to androgen independence with the T allele (P = 0.048). CONCLUSION: A polymorphism in a transporter that increases testosterone import is associated with a shorter time to androgen independence in patients with prostate cancer who are treated with ADT.

Original languageEnglish (US)
Pages (from-to)617-621
Number of pages5
JournalBJU International
Volume102
Issue number5
DOIs
StatePublished - Sep 2008

Fingerprint

Androgens
Testosterone
Prostatic Neoplasms
Alleles
Prostate-Specific Antigen
Therapeutics
Survival

Keywords

  • Androgen deprivation
  • Androgen independence
  • Hormonal therapy
  • Prostate cancer
  • Testosterone
  • Transporter

ASJC Scopus subject areas

  • Urology

Cite this

Sharifi, N., Hamada, A., Sissung, T., Danesi, R., Venzon, D., Baum, C., ... Figg, W. D. (2008). A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer. BJU International, 102(5), 617-621. https://doi.org/10.1111/j.1464-410X.2008.07629.x

A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer. / Sharifi, Nima; Hamada, Akinobu; Sissung, Tristan; Danesi, Romano; Venzon, David; Baum, Caitlin; Gulley, James L.; Price, Douglas K.; Dahut, William L.; Figg, William D.

In: BJU International, Vol. 102, No. 5, 09.2008, p. 617-621.

Research output: Contribution to journalArticle

Sharifi, N, Hamada, A, Sissung, T, Danesi, R, Venzon, D, Baum, C, Gulley, JL, Price, DK, Dahut, WL & Figg, WD 2008, 'A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer', BJU International, vol. 102, no. 5, pp. 617-621. https://doi.org/10.1111/j.1464-410X.2008.07629.x
Sharifi, Nima ; Hamada, Akinobu ; Sissung, Tristan ; Danesi, Romano ; Venzon, David ; Baum, Caitlin ; Gulley, James L. ; Price, Douglas K. ; Dahut, William L. ; Figg, William D. / A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer. In: BJU International. 2008 ; Vol. 102, No. 5. pp. 617-621.
@article{7b548540f9944ac8b26cf3ced0b52c8e,
title = "A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer",
abstract = "OBJECTIVE: To determine if patients with advanced prostate cancer carrying a polymorphism that codes for a more active testosterone transporter have less durable responses to androgen-deprivation therapy (ADT) than patients not carrying this polymorphism. PATIENTS AND METHODS: We previously determined that a polymorphism in SLCO1B3 affects testosterone transport and that those men who have at least one wild-type T allele at the 334 T > G polymorphism in this gene have a shorter survival. We hypothesized that the T allele which increases testosterone transport would be associated with a shorter interval from ADT to androgen independence. We examined the association between this SLCO1B3 polymorphism and time from ADT to androgen independence, ADT to prostate-specific antigen (PSA) nadir and PSA nadir to androgen independence in 68 Caucasian patients with advanced prostate cancer who were treated with ADT with metastatic disease (D2) or biochemical failure with no metastatic disease (D0). RESULTS: When examined separately, patients in the individual stages tended to have a shorter time to androgen independence with the T allele in the D0 (P = 0.11) and D2 (P = 0.18) groups. Combining these groups and stratifying by stage yielded a statistically significant shorter time to androgen independence with the T allele (P = 0.048). CONCLUSION: A polymorphism in a transporter that increases testosterone import is associated with a shorter time to androgen independence in patients with prostate cancer who are treated with ADT.",
keywords = "Androgen deprivation, Androgen independence, Hormonal therapy, Prostate cancer, Testosterone, Transporter",
author = "Nima Sharifi and Akinobu Hamada and Tristan Sissung and Romano Danesi and David Venzon and Caitlin Baum and Gulley, {James L.} and Price, {Douglas K.} and Dahut, {William L.} and Figg, {William D.}",
year = "2008",
month = "9",
doi = "10.1111/j.1464-410X.2008.07629.x",
language = "English (US)",
volume = "102",
pages = "617--621",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer

AU - Sharifi, Nima

AU - Hamada, Akinobu

AU - Sissung, Tristan

AU - Danesi, Romano

AU - Venzon, David

AU - Baum, Caitlin

AU - Gulley, James L.

AU - Price, Douglas K.

AU - Dahut, William L.

AU - Figg, William D.

PY - 2008/9

Y1 - 2008/9

N2 - OBJECTIVE: To determine if patients with advanced prostate cancer carrying a polymorphism that codes for a more active testosterone transporter have less durable responses to androgen-deprivation therapy (ADT) than patients not carrying this polymorphism. PATIENTS AND METHODS: We previously determined that a polymorphism in SLCO1B3 affects testosterone transport and that those men who have at least one wild-type T allele at the 334 T > G polymorphism in this gene have a shorter survival. We hypothesized that the T allele which increases testosterone transport would be associated with a shorter interval from ADT to androgen independence. We examined the association between this SLCO1B3 polymorphism and time from ADT to androgen independence, ADT to prostate-specific antigen (PSA) nadir and PSA nadir to androgen independence in 68 Caucasian patients with advanced prostate cancer who were treated with ADT with metastatic disease (D2) or biochemical failure with no metastatic disease (D0). RESULTS: When examined separately, patients in the individual stages tended to have a shorter time to androgen independence with the T allele in the D0 (P = 0.11) and D2 (P = 0.18) groups. Combining these groups and stratifying by stage yielded a statistically significant shorter time to androgen independence with the T allele (P = 0.048). CONCLUSION: A polymorphism in a transporter that increases testosterone import is associated with a shorter time to androgen independence in patients with prostate cancer who are treated with ADT.

AB - OBJECTIVE: To determine if patients with advanced prostate cancer carrying a polymorphism that codes for a more active testosterone transporter have less durable responses to androgen-deprivation therapy (ADT) than patients not carrying this polymorphism. PATIENTS AND METHODS: We previously determined that a polymorphism in SLCO1B3 affects testosterone transport and that those men who have at least one wild-type T allele at the 334 T > G polymorphism in this gene have a shorter survival. We hypothesized that the T allele which increases testosterone transport would be associated with a shorter interval from ADT to androgen independence. We examined the association between this SLCO1B3 polymorphism and time from ADT to androgen independence, ADT to prostate-specific antigen (PSA) nadir and PSA nadir to androgen independence in 68 Caucasian patients with advanced prostate cancer who were treated with ADT with metastatic disease (D2) or biochemical failure with no metastatic disease (D0). RESULTS: When examined separately, patients in the individual stages tended to have a shorter time to androgen independence with the T allele in the D0 (P = 0.11) and D2 (P = 0.18) groups. Combining these groups and stratifying by stage yielded a statistically significant shorter time to androgen independence with the T allele (P = 0.048). CONCLUSION: A polymorphism in a transporter that increases testosterone import is associated with a shorter time to androgen independence in patients with prostate cancer who are treated with ADT.

KW - Androgen deprivation

KW - Androgen independence

KW - Hormonal therapy

KW - Prostate cancer

KW - Testosterone

KW - Transporter

UR - http://www.scopus.com/inward/record.url?scp=48749103948&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48749103948&partnerID=8YFLogxK

U2 - 10.1111/j.1464-410X.2008.07629.x

DO - 10.1111/j.1464-410X.2008.07629.x

M3 - Article

C2 - 18537956

AN - SCOPUS:48749103948

VL - 102

SP - 617

EP - 621

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 5

ER -